BioNTech (NASDAQ:BNTX) Receives “Buy” Rating from Jefferies Financial Group

Posted by Francis Steltz on Jun 1st, 2026

BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a research note issued to investors on Monday,MarketScreener reports.

Several other research analysts have also recently issued reports on BNTX. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $130.00 price objective on shares of BioNTech in a report on Monday, April 27th. Canaccord Genuity Group lowered their target price on shares of BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. BMO Capital Markets dropped their price target on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Finally, TD Cowen reduced their price target on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.56.

Read Our Latest Research Report on BNTX

BioNTech Stock Performance

Shares of NASDAQ BNTX traded down $3.72 during midday trading on Monday, hitting $92.24. 243,439 shares of the company’s stock were exchanged, compared to its average volume of 1,057,374. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74. The stock’s 50 day moving average price is $94.46 and its 200-day moving average price is $99.45. The firm has a market cap of $23.32 billion, a P/E ratio of -15.68 and a beta of 1.33. BioNTech has a twelve month low of $79.52 and a twelve month high of $124.00.

BioNTech (NASDAQ:BNTX – Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion during the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. Equities research analysts anticipate that BioNTech will post -4.71 EPS for the current year.

BioNTech announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to reacquire up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the transaction, the chief operating officer directly owned 399,387 shares of the company’s stock, valued at $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the business. Dodge & Cox grew its stake in shares of BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after purchasing an additional 2,769,654 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in BioNTech by 43.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Bank of America Corp DE boosted its holdings in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after buying an additional 166,432 shares in the last quarter. GSK plc bought a new stake in BioNTech during the fourth quarter worth approximately $84,711,000. Finally, First Trust Advisors LP grew its position in BioNTech by 116.0% in the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after buying an additional 451,124 shares during the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

(Get Free Report)

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.